SAN DIEGO--(BUSINESS WIRE)--OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced a collaboration with PerkinElmer, Inc. and the University of California, Los Angeles (UCLA) to help researchers develop biomarker tests to evaluate a patient’s immune response to cancer. This research supports the ongoing shift in oncology toward therapeutic strategies that stimulate the patient’s own immune defense system to combat cancer. The approach uses PerkinElmer’s new imaging-based staining methods to quantitatively evaluate CD8+ T cell density in tumor biopsies.
Help employers find you! Check out all the jobs and post your resume.
